Liver RegenerationNCT02113059
Platelets in Liver Regeneration
An observational study of Liver Regeneration, run by Medical University of Vienna at 2 sites in Austria.
Trial summary
The most relevant factor predicting morbidity and mortality after liver resections is the ability of the remnant liver to regenerate. The investigators recently demonstrated that serotonin and thrombospondin-1, two growth factors abundantly stored in platelets, seem to play a critical role in liver regeneration of… Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Liver Regeneration
- How many people
- 40 participants
- Where
- 2 sitesAustria
- Study dates
- Nov 2012to Apr 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 80 patients undergoing elective hemihepatectomy.
Who may be able to join
- patients undergoing elective hemihepatectomy
Who cannot join
- peroperative portal vein thrombosis
- age > 85
Trial locations and contacts
2 sites in 1 country.
Austria2 sites, 2 recruiting
- Recruiting
Rudolfstiftung
Vienna, 1030
Thomas Gruenberger, MD, (+43 1) 711 65 - 0, thomas.gruenberger@meduniwien.ac.at
- Recruiting
Medical University Vienna
Vienna, 1090
Patrick Starlinger, 00431404005621, patrick.starlinger@meduniwien.ac.at
Thomas Gruenberger, 00431404005621, thomas.gruenberger@meduniwien.ac.at
About this study
Official title: "Involvement of Platelets and Platelet Derived Growth Factors in Postoperative Liver Regeneration, Liver Dysfunktion and Morbidity in Patients Undergoing Hepatectomy"
The most relevant factor predicting morbidity and mortality after liver resections is the ability of the remnant liver to regenerate. The investigators recently demonstrated that serotonin and thrombospondin-1, two growth factors abundantly stored in platelets, seem to play a critical role in liver regeneration of patients after liver resection. The investigators now aim to gain more precise insight concerning the relevance of platelets and platelet derived growth factors in liver regeneration in humans. The investigators will focus on specific alpha-granula release as a key regulator of postoperative LR. Using peri- and intraoperative blood and tissue samples, platelet adhesion, granula release and induction of gene expression known to be involved in liver regeneration form experimental studies will be analyzed. This study should allow the investigators to verify observations from preclinical models and evaluate their relevance in the human setting. Furthermore, this might enable the investigators to identify new therapeutic targets.
Read the detailed description
The investigators could previously show that platelet derived growth factors like TSP-1 and 5-HT are of relevance in human liver regeneration. In this project the investigators aim to elucidate how platelets specifically release their granules. Indeed, while dense granules stored 5-HT induces proliferation of hepatocytes, alpha-granules stored TSP-1 reduces their proliferative potential. More importantly, various pro-proliferative growth factors as VEGF are also stored in alpha-granules. Therefore, a systemic reduction in platelet counts would reduce both, pro and anti-proliferative factors. A highly regulated granula release has been postulated to allow platelets to exert specific functions. In 2008, Italiano et al. presented convincing in vitro evidence that platelets store molecules in separate granules, which they are able to specifically release upon platelet activation. Furthermore, results by other groups support this finding.
It is the aim of this project to characterize platelet activation in patients with liver resection and determine if specific platelet activation profiles correlate with clinical outcome.
Project plan
Included patients:
A total of 40 patients undergoing hemihepatectomy will be included. Patients will be closely monitored perioperatively. Plasma, serum, platelet and tissue preparation will be performed as outlined below.
Hypothesis No. 1:
Circulating platelet activation markers increase after liver resection.
To confirm the investigators initial observation of specific granula release, platelet activation will be monitored during liver regeneration. In particular, the investigators will evaluate platelet activation markers during the perioperative period. In a descriptive manner, the investigators will identify perioperative fluctuations of platelet activation as a reflection of physiologic processes during liver regeneration. This should enable the investigators to elucidate the occurrence of platelet activation in the human setting, as it has been described in murine models. More importantly, the investigators analyses could identify potential treatment targets in patients with insufficient hepatic regeneration.
Hypothesis No. 2:
Intra platelet granula contents decrease after liver resection.
Bioactive molecules stored in platelet alpha granules (intra platelet - IP), will be evaluated during the perioperative period. As during serum preparation all platelets degranulate, IP levels of granula contents will be calculated by subtraction of plasma from serum growth factor values. Furthermore to confirm these calculated values, platelet extracts will be generated and comparatively analyzed for IP growth factor levels. The investigators will further be able to identify perioperative fluctuations of IP growth factors as a reflection of specific intrahepatic release during liver regeneration, by comparing blood samples prior and one day after liver resection.
Hypothesis No. 3:
Platelets are locally enriched and activated at the site of liver regeneration.
During the process of a classical hemihepatectomy, the portal vein of the tumor containing liver lobe is initially ligated before mobilization and dissection of the liver. The increase of portal pressure within the remaining liver after partial hepatectomy is believed to be the major inducer of liver regeneration. (37-40) To evaluate if platelets play a critical role during the process of initiation of liver regeneration, tissue specimens will be collected prior to portal vein ligation and one hour after portal vein ligation (at the time of initiation of liver regeneration)(study design is illustrated in figure 3). Liver specimens will then be comparatively analyzed for platelet adhesion and protein as well as mRNA expression.
To further evaluate the relevance of platelets in the tightly regulated process of liver regeneration, blood will be collected 1 hour after portal vein ligation. In particular, blood will be drawn from the portal vein (prior to the liver) and from a liver vein (after the liver). From these samples platelets will be isolated and the degree of activation will be evaluated (details see below). Furthermore, the content of IP growth factors and platelet extracts will be analyzed to reflect their intrahepatic release.
Hypothesis No. 4:
Perioperative platelet activation has an impact on postoperative outcome
The predictive potential of platelet activation markers and IP growth factors to identify patients with poor postoperative clinical outcome will be analyzed. As outcome parameters postoperative LD, morbidity or mortality will be evaluated. These analyses might identify markers to select patients that should not undergo hepatectomy but be better served with alternative treatments. Furthermore, potential treatment targets in patients with insufficient hepatic regeneration could be identified.
- Conditions
- Liver Regeneration
- Keywords
- Liver regeneration, liver dysfunction, platelets, plasma, serum, platelet activation, morbidity, mortality, Growth factors, Postoperative clinical outcome
- Medical subject headings
- Liver Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Liver resection | Patients undergoing a hemihepatectomy. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Validation of the role of platelets in the process of early liver regeneration in humans
Preclinical studies have identified multiple platelet associated candidate molecules in the highly regulated process of liver regeneration. Using a complex peri and intraoperative sampling schedule, we will try to validate the relevance of these molecules in the human setting.
Measured: 2 years
Secondary outcomes (2)
Postoperative liver dysfunction
Association of peri and intraoperative blood and tissue parameters associated with postoperative liver dysfunction
Measured: 2 years
Postoperative morbidity
Association of peri and intraoperative blood and tissue parameters associated with postoperative morbidity
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2014 (estimated)
- Study startNov 2012
- Primary completionApr 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver RegenerationStudies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Patrick Starlinger, Medical University of Vienna
- Investigators
- Patrick Starlinger, MD, PhD, Principal investigator, Medical University of ViennaAlice Assinger, PhD, Principal investigator, Medical University of Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02113059
- Sponsor's protocol ID
- PS-AS-TG-CB
- Status last verified
- Nov 2016
- First submitted
- 6 Apr 2014
- Last updated
- 7 Nov 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Nov 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Involvement of Platelets and Platelet Derived Growth Factors in Postoperative Liver Regeneration, Liver Dysfunktion and Morbidity in Patients Undergoing Hepatectomy"
- ClinicalTrials.gov ID
- NCT02113059
- Acronym / sponsor ID
- PS-AS-TG-CB
- Conditions
- Liver Regeneration
- Keywords
- Liver regeneration, liver dysfunction, platelets, plasma, serum, platelet activation, morbidity, mortality
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Study start
- Nov 2012
- Primary completion
- Apr 2017 (estimated)
- First posted
- 14 Apr 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The most relevant factor predicting morbidity and mortality after liver resections is the ability of the remnant liver to regenerate. The investigators recently demonstrated that serotonin and thrombospondin-1, two growth factors abundantly stored in platelets, seem to play a critical role in liver regeneration of patients after liver resection. The investigators now aim to gain more precise insight concerning the relevance of platelets and platelet derived growth factors in liver regeneration in humans. The investigators will focus on specific alpha-granula release as a key regulator of postoperative LR. Using peri- and intraoperative blood and tissue samples, platelet adhesion, granula release and induction of gene expression known to be involved in liver regeneration form experimental studies will be analyzed. This study should allow the investigators to verify observations from preclinical models and evaluate their relevance in the human setting. Furthermore, this might enable the investigators to identify new therapeutic targets.
Detailed description
The investigators could previously show that platelet derived growth factors like TSP-1 and 5-HT are of relevance in human liver regeneration. In this project the investigators aim to elucidate how platelets specifically release their granules. Indeed, while dense granules stored 5-HT induces proliferation of hepatocytes, alpha-granules stored TSP-1 reduces their proliferative potential. More importantly, various pro-proliferative growth factors as VEGF are also stored in alpha-granules. Therefore, a systemic reduction in platelet counts would reduce both, pro and anti-proliferative factors. A highly regulated granula release has been postulated to allow platelets to exert specific functions. In 2008, Italiano et al. presented convincing in vitro evidence that platelets store molecules in separate granules, which they are able to specifically release upon platelet activation. Furthermore, results by other groups support this finding.
It is the aim of this project to characterize platelet activation in patients with liver resection and determine if specific platelet activation profiles correlate with clinical outcome.
Project plan
Included patients:
A total of 40 patients undergoing hemihepatectomy will be included. Patients will be closely monitored perioperatively. Plasma, serum, platelet and tissue preparation will be performed as outlined below.
Hypothesis No. 1:
Circulating platelet activation markers increase after liver resection.
To confirm the investigators initial observation of specific granula release, platelet activation will be monitored during liver regeneration. In particular, the investigators will evaluate platelet activation markers during the perioperative period. In a descriptive manner, the investigators will identify perioperative fluctuations of platelet activation as a reflection of physiologic processes during liver regeneration. This should enable the investigators to elucidate the occurrence of platelet activation in the human setting, as it has been described in murine models. More importantly, the investigators analyses could identify potential treatment targets in patients with insufficient hepatic regeneration.
Hypothesis No. 2:
Intra platelet granula contents decrease after liver resection.
Bioactive molecules stored in platelet alpha granules (intra platelet - IP), will be evaluated during the perioperative period. As during serum preparation all platelets degranulate, IP levels of granula contents will be calculated by subtraction of plasma from serum growth factor values. Furthermore to confirm these calculated values, platelet extracts will be generated and comparatively analyzed for IP growth factor levels. The investigators will further be able to identify perioperative fluctuations of IP growth factors as a reflection of specific intrahepatic release during liver regeneration, by comparing blood samples prior and one day after liver resection.
Hypothesis No. 3:
Platelets are locally enriched and activated at the site of liver regeneration.
During the process of a classical hemihepatectomy, the portal vein of the tumor containing liver lobe is initially ligated before mobilization and dissection of the liver. The increase of portal pressure within the remaining liver after partial hepatectomy is believed to be the major inducer of liver regeneration. (37-40) To evaluate if platelets play a critical role during the process of initiation of liver regeneration, tissue specimens will be collected prior to portal vein ligation and one hour after portal vein ligation (at the time of initiation of liver regeneration)(study design is illustrated in figure 3). Liver specimens will then be comparatively analyzed for platelet adhesion and protein as well as mRNA expression.
To further evaluate the relevance of platelets in the tightly regulated process of liver regeneration, blood will be collected 1 hour after portal vein ligation. In particular, blood will be drawn from the portal vein (prior to the liver) and from a liver vein (after the liver). From these samples platelets will be isolated and the degree of activation will be evaluated (details see below). Furthermore, the content of IP growth factors and platelet extracts will be analyzed to reflect their intrahepatic release.
Hypothesis No. 4:
Perioperative platelet activation has an impact on postoperative outcome
The predictive potential of platelet activation markers and IP growth factors to identify patients with poor postoperative clinical outcome will be analyzed. As outcome parameters postoperative LD, morbidity or mortality will be evaluated. These analyses might identify markers to select patients that should not undergo hepatectomy but be better served with alternative treatments. Furthermore, potential treatment targets in patients with insufficient hepatic regeneration could be identified.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Liver resection | – | –Patients undergoing a hemihepatectomy. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 80 patients undergoing elective hemihepatectomy.
Key inclusion criteria (1 listed)
- patients undergoing elective hemihepatectomy
Key exclusion criteria (2 listed)
- peroperative portal vein thrombosis
- age > 85
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Validation of the role of platelets in the process of early liver regeneration in humans
Time frame: 2 years
Preclinical studies have identified multiple platelet associated candidate molecules in the highly regulated process of liver regeneration. Using a complex peri and intraoperative sampling schedule, we will try to validate the relevance of these molecules in the human setting.
2 secondary outcomes
Postoperative liver dysfunction
Time frame: 2 years
Postoperative morbidity
Time frame: 2 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Nov 2016.
Related trials for Liver Regeneration
Not yet recruitingPhase 2
HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
Not yet recruiting
Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration in Adult Living Donor Liver Transplant (LDLT) Recipients.
Chronic Liver Disease
Enrolling by invitationObservational study
The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study
Living Donor Liver Transplantation
Not yet recruiting
Renal Histopathology and Transcriptomic Analysis in Hepatorenal Syndrome During Liver Transplantation
Hepatorenal Syndrome, Liver Regeneration, AKI - Acute Kidney Injury
RecruitingObservational study
Effect and Mechanism of ALPPS Operation on Liver Regeneration
Hepato Cellular Carcinoma (HCC), Hepatobiliary Cancers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Patrick Starlinger, MD, PhD principal investigator
Medical University of Vienna
Alice Assinger, PhD principal investigator
Medical University of Vienna
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Regeneration, run by Medical University of Vienna at 2 sites in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 7 Nov 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Patrick Starlinger, MD, PhD (0043 40400 5621, patrick.starlinger@meduniwien.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Validation of the role of platelets in the process of early liver regeneration in humans (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2016.